意义未明的低风险单克隆丙种球蛋白病的骨髓活检揭示了一个新的冒烟型多发性骨髓瘤风险组。 - Suppr

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

作者信息

Bustoros Mark, Kastritis Efstathios, Sklavenitis-Pistofidis Romanos, Liu Chia-Jen, Hornburg Kalvis, Kanellias Nikolaos, Kim Geon, Liu David, Gavriatopoulou Maria, Marinac Catherine R, Roussou Maria, Migkou Magdalini, Noonan Kimberly, Reyes Kaitlen, Rivotto Bradley, Neuse Carl Jannes, Ziogas Dimitrios C, Laubach Jacob, Terpos Evangelos, Anderson Kenneth C, Richardson Paul G, Ghobrial Irene M, Dimopoulos Meletios A

机构信息

Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

出版信息

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6.

DOI:10.1002/ajh.25441

PMID:30773670

Abstract

摘要

相似文献

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6.

High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Best Pract Res Clin Haematol. 2020 Mar;33(1):101152. doi: 10.1016/j.beha.2020.101152. Epub 2020 Jan 25.

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Leukemia. 2020 Dec;34(12):3111-3125. doi: 10.1038/s41375-020-01051-x. Epub 2020 Oct 12.

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Blood Cancer J. 2020 May 6;10(5):52. doi: 10.1038/s41408-020-0319-0.

Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.

Br J Haematol. 2017 Dec;179(5):849-851. doi: 10.1111/bjh.14266. Epub 2016 Sep 8.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22.

Risk Stratification of Precursors to Multiple Myeloma in 2020.

R I Med J (2013). 2020 Apr 1;103(3):46-47.

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

Br J Haematol. 2024 Apr;204(4):1193-1206. doi: 10.1111/bjh.19333. Epub 2024 Feb 23.

Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.

Leuk Lymphoma. 2018 Jan;59(1):178-186. doi: 10.1080/10428194.2017.1321746. Epub 2017 May 25.

Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Clin Biochem. 2018 Jan;51:38-47. doi: 10.1016/j.clinbiochem.2017.05.001. Epub 2017 May 4.

引用本文的文献

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.

Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.

Front Oncol. 2022 Jul 14;12:961421. doi: 10.3389/fonc.2022.961421. eCollection 2022.

A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea.

Sci Rep. 2021 Sep 16;11(1):18449. doi: 10.1038/s41598-021-97664-y.

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.

Progress in the Management of Smoldering Multiple Myeloma.

Curr Hematol Malig Rep. 2021 Apr;16(2):172-182. doi: 10.1007/s11899-021-00623-7. Epub 2021 May 13.

What Is New in the Treatment of Smoldering Multiple Myeloma?

J Clin Med. 2021 Jan 22;10(3):421. doi: 10.3390/jcm10030421.

How we manage smoldering multiple myeloma.

Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

作者信息

机构信息

Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

出版信息

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6.

DOI:10.1002/ajh.25441

PMID:30773670

Abstract

摘要

相似文献

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6.

High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Best Pract Res Clin Haematol. 2020 Mar;33(1):101152. doi: 10.1016/j.beha.2020.101152. Epub 2020 Jan 25.

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Leukemia. 2020 Dec;34(12):3111-3125. doi: 10.1038/s41375-020-01051-x. Epub 2020 Oct 12.

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Blood Cancer J. 2020 May 6;10(5):52. doi: 10.1038/s41408-020-0319-0.

Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.

Br J Haematol. 2017 Dec;179(5):849-851. doi: 10.1111/bjh.14266. Epub 2016 Sep 8.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22.

Risk Stratification of Precursors to Multiple Myeloma in 2020.

R I Med J (2013). 2020 Apr 1;103(3):46-47.

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

Br J Haematol. 2024 Apr;204(4):1193-1206. doi: 10.1111/bjh.19333. Epub 2024 Feb 23.

Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.

Leuk Lymphoma. 2018 Jan;59(1):178-186. doi: 10.1080/10428194.2017.1321746. Epub 2017 May 25.

Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Clin Biochem. 2018 Jan;51:38-47. doi: 10.1016/j.clinbiochem.2017.05.001. Epub 2017 May 4.

引用本文的文献

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.

Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.

Front Oncol. 2022 Jul 14;12:961421. doi: 10.3389/fonc.2022.961421. eCollection 2022.

A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea.

Sci Rep. 2021 Sep 16;11(1):18449. doi: 10.1038/s41598-021-97664-y.

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.

Progress in the Management of Smoldering Multiple Myeloma.

Curr Hematol Malig Rep. 2021 Apr;16(2):172-182. doi: 10.1007/s11899-021-00623-7. Epub 2021 May 13.

What Is New in the Treatment of Smoldering Multiple Myeloma?

J Clin Med. 2021 Jan 22;10(3):421. doi: 10.3390/jcm10030421.

How we manage smoldering multiple myeloma.

Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

作者信息

机构信息

出版信息

相似文献

引用本文的文献